>
Rhinomed logo

RNO - Rhinomed Share Price

A$0.165 0.0  3.1%

Last Trade - 14/05/21

Sector
Healthcare
Size
Micro Cap
Market Cap £23.0m
Enterprise Value £20.3m
Revenue £2.13m
Position in Universe 1215th / 1911
Bullish
Bearish
Unlock RNO Revenue
Momentum
Relative Strength (%)
1m +44.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.49 1.04 1.74 2.18 3.30 3.58 10.6 16.2 +49.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, RhinomedLtd revenues increased 17% to A$2M. Net loss increased 4%to A$5.5M. Revenues reflect Interest income increase fromA$8K to A$20K. Higher net loss reflects Employee benefitexpense increase from A$1.6M to A$3.6M (expense), Otherexpenses increase of 40% to A$690K (expense), Research anddevelopment increase from A$101K to A$255K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

RNO Revenue Unlock RNO Revenue

Net Income

RNO Net Income Unlock RNO Revenue

Normalised EPS

RNO Normalised EPS Unlock RNO Revenue

PE Ratio Range

RNO PE Ratio Range Unlock RNO Revenue

Dividend Yield Range

RNO Dividend Yield Range Unlock RNO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RNO EPS Forecasts Unlock RNO Revenue
Profile Summary

Rhinomed Limited is an Australia-based medical technology company. The Company is engaged in the research, development and commercialization of consumer and medical devices. The Company is involved in the identification, acquisition and commercialization of late-stage therapeutic delivery technologies. Its over-the-counter (OTC) products, including Turbine and Mute, are sold online and through pharmacies, sleep clinics and sports stores. Its Turbine is a nasal dilator designed to assist the user to breathe during aerobic exercise. Its Mute is a nasal technology that is designed to allow the user to manage the sleep quality by breathing more and snoring less. Its Intranasal Positive Expiratory Air Pressure (INPEAP) technology is under development for the treatment of mild to moderate obstructive sleep apnea. In addition, the Company is involved in clinical programs that are focused on the olfactory pathway and wearable technology.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated February 9, 2004
Public Since December 1, 1987
No. of Shareholders: 1,216
No. of Employees: n/a
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange Australian Stock Exchange - SEATS
Shares in Issue 253,809,132
Free Float (0.0%)
Eligible for
ISAs
SIPPs
RNO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for RNO
Upcoming Events for RNO
Frequently Asked Questions for Rhinomed
What is the Rhinomed share price?

As of 14/05/21, shares in Rhinomed are trading at A$0.165, giving the company a market capitalisation of £23.0m. This share price information is delayed by 15 minutes.

How has the Rhinomed share price performed this year?

Shares in Rhinomed are currently trading at A$0.165 and the price has moved by 0.126k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Rhinomed price has moved by 69.16% over the past year.

What are the analyst and broker recommendations for Rhinomed?

Of the analysts with advisory recommendations for Rhinomed, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Rhinomed is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Rhinomed next release its financial results?

Rhinomed is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Rhinomed dividend yield?

Rhinomed does not currently pay a dividend.

Does Rhinomed pay a dividend?

Rhinomed does not currently pay a dividend.

When does Rhinomed next pay dividends?

Rhinomed does not currently pay a dividend.

How do I buy Rhinomed shares?

To buy shares in Rhinomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Rhinomed?

Shares in Rhinomed are currently trading at A$0.165, giving the company a market capitalisation of £23.0m.

Where are Rhinomed shares listed? Where are Rhinomed shares listed?

Here are the trading details for Rhinomed:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: RNO
What kind of share is Rhinomed?

Based on an overall assessment of its quality, value and momentum, Rhinomed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Rhinomed share price forecast 2021?

Shares in Rhinomed are currently priced at A$0.165. At that level they are trading at 33.33% discount to the analyst consensus target price of 0.00.

Analysts covering Rhinomed currently have a consensus Earnings Per Share (EPS) forecast of 0.01 for the next financial year.

How can I tell whether the Rhinomed share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhinomed. Over the past six months, the relative strength of its shares against the market has been -12.91%. At the current price of A$0.165, shares in Rhinomed are trading at 23.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Rhinomed PE Ratio?

We were not able to find PE ratio data for Rhinomed.

Who are the key directors of Rhinomed?

Rhinomed's management team is headed by:

Michael Johnson - CEO
Brent Scrimshaw - NED
Eric Knight - NED
Ronald Dewhurst - CHM
Sean Slattery - SEC
Who are the major shareholders of Rhinomed?

Here are the top five shareholders of Rhinomed based on the size of their shareholding:

George (W. Whitney) Individual Investor
Percentage owned: 40.1% (101.8m shares)
Fifty Second Celebration Pty. Ltd. Corporation
Percentage owned: 11.09% (28.2m shares)
Thirty-Fifth Celebration Pty. Ltd. Corporation
Percentage owned: 6.16% (15.6m shares)
Dewhurst (Ronald Richard) Individual Investor
Percentage owned: 5.81% (14.8m shares)
Kroy Wen Pty. Ltd. Corporation
Percentage owned: 5.22% (13.3m shares)
Similar to RNO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.